

CADTH RAPID RESPONSE REPORT: REFERENCE LIST

# Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogviri

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: February 4, 2019  
Report Length: 4 Pages

**Authors:** Susan Mirabi, Kimberly Castellano , Carolyn Spry

**Cite As:** *Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogivri*. Ottawa: CADTH; 2019 Feb.. (CADTH rapid response report: reference list).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Research Questions

1. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with early breast cancer (EBC)?
2. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with metastatic breast cancer (MBC)?
3. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with metastatic gastric cancer (MGC)?

## Key Findings

No relevant literature was identified regarding the clinical effectiveness of switching from Ogivri or other biosimilars to Herceptin for patients with EBC, MBC or MGC.

## Methods

A limited literature search was conducted on key resources including Medline, PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit retrieval by publication type. The search was limited to English language documents but was not limited by publication date. Internet links were provided, where available.

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Q1: patients with early breast cancer Q2: patients with metastatic breast cancer Q3: patients with metastatic gastric cancer
<b>Intervention</b>	Switching to Ogivri (a <i>trastuzumab</i> biosimilar)
<b>Comparator</b>	Use of <i>Herceptin</i> (reference biologic) or other <i>trastuzumab</i> biosimilars
<b>Outcomes</b>	Clinical Effectiveness Q1: progression-free survival; overall survival; disease free survival; health-related quality of life; harms Q2: progression-free survival; overall survival; health-related quality of life; time to progression; duration of response; objective response rate; harms Q3: progression-free survival; overall survival; health-related quality of life; time of progression; disease control rate; duration of response; objective response rate; harms
<b>Study Designs</b>	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies

## Results

No relevant health technology assessment reports, systematic reviews, meta-analyses, randomized controlled trials, or non-randomized studies regarding the clinical effectiveness of switching from Ogivri or other biosimilars to Herceptin for patients with EBC, MBC or MGC were identified.

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Randomized Controlled Trials

No literature identified.

### Non-Randomized Studies

No literature identified.